People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other Health Care, Pharma, Computers, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abcuro, Inc. | — | Biotechnology | Series D+ | $225.9M | $718.8M | 2020 |
| MacuLogix, Inc. | — | Other Health Care | Series B | $82.1M | $163.6M | 2012 |
| ImmuneXcite, Inc. | — | Biotechnology | Series A | $17.6M | $96.6M | 2015 |
| PanTher Therapeutics, Inc. | — | Pharma | Series A | $15.8M | $11.4M | 2023 |
| Move Networks Inc | — | Computers | Series A | $10.8M | $99.7M | 2009 |
| Permeon Biologics, Inc. | — | Pharmaceuticals | Seed | $6.0M | $95.1M | 2011 |
| Tilos Therapeutics, Inc. | — | Biotechnology | Seed | $3.8M | $135.4M | 2017 |
| Renova PCA, LLC | — | Other Health Care | Pre-Seed | $100K | $3.1M | 2016 |
John Edwards at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Edwards on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.